What clinicians need to know about intranasal esketamine for treatment-resistant depression?

CONCLUSION: Intranasal esketamine plus antidepressant has been approved by regulators as moderately effective and acceptably tolerable for treatment-resistant depression. Cost is a drawback. Use often needs to be long-term and vigilance for abuse is essential.PMID:37961848 | DOI:10.1177/10398562231211171

Source: Australasian Psychiatry - November 14, 2023 Category: Psychiatry Authors: Judy Hope David Copolov John Tiller Megan Galbally Malcolm Hopwood Richard Newton Nicholas A Keks Source Type: research